Here are three fairly recent (past couple of years) deals that took place. I posted this a few months ago but wanted to bring it up again. When you compare what was bought in these acquisitions to what ONCS currently has you can see why many are saying ONCS is the most undervalued bio-tech out there right now.
$425MM in cash plus $575MM in payments for regulatory and sale milestones
1 drug in Phase 3 that was recruiting patients
1 drug under development in the UK
An operational manufacturing facility
Amgen-Micromet $1.16B in cash
1 drug under going multiple trials with no further progression than ongoing Phase 2s
Proprietary BiTE antibody technology for future research and potential milestone/royalty payments from licensing
Rights to one antibody in Phase 1
A site for R&D
$350MM in cash plus $195MM for milestones of the drug's successful development and approval, plus $380MM for milestones from drugs developed and approved from the platform
1 drug in Phase 1
Proprietary Avilomics Platform for discovery and development
What does OncoSec have to offer:
Ready for market
CE Mark for Europe,
Patent for China for method of use and device.
Phase 2 Malignant Melanoma
Phase 2 Merkel Cell Carcinoma
Phase 2 Cutaneous T-cell Lymphoma
Producing outstanding data thus far, in fact leading the way with their results.
Research program with Old Dominion University
ONCS is a diamond in the rough, the potential here is more than what you will find just about anywhere. Of course there are no guarantees, but the data to date has been outstanding, clearly beyond any of their competitors. Myself, I am buying and holding all I can for it is only a matter of time until ONCS' pps moves to the other side of the decimal place.